メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
感染症学
医学部
医学部基礎教室
概要
フィンガープリント
ネットワーク
プロファイル
(4)
研究成果
(537)
フィンガープリント
感染症学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lung Injury
40%
Acute Otitis Media
16%
Adult Respiratory Distress Syndrome
18%
Adverse Drug Reaction
14%
Adverse Event
24%
Alanine Aminotransferase
8%
Amikacin
9%
Antibiotic Agent
17%
Antibiotics
19%
Antiinfective Agent
18%
Aspartate Aminotransferase
11%
Atypical Mycobacteriosis
11%
Atypical Mycobacterium
7%
Bacteremia
13%
Bacterial Infection
8%
Bacterial Pneumonia
11%
Biological Marker
17%
Bleomycin
8%
Bronchiectasis
17%
C Reactive Protein
8%
Ceftazidime
13%
Chemotherapy
10%
Chronic Obstructive Lung Disease
15%
Chronic Respiratory Tract Disease
8%
Clarithromycin
19%
Clinical Feature
14%
Clinical Study
33%
Clinical Trial
31%
Cohort Study
18%
Collagen Type 7
8%
Combination Therapy
11%
Community Acquired Pneumonia
13%
Coronavirinae
36%
Cross-Sectional Study
17%
Diarrhea
18%
Dipeptidyl Peptidase I
9%
Disease
100%
Disease Exacerbation
10%
DNA Polymerase
8%
Doxycycline
8%
Elastase-Induced Emphysema
10%
Emphysema
9%
Endotoxin
23%
Entamoeba Histolytica
13%
Escherichia coli
10%
Fibrosing Alveolitis
13%
Gamma Interferon
8%
Gentamicin
18%
Guinea Pig
13%
Haemophilus influenzae
27%
Heparin
8%
Immaturity
8%
Infection
94%
Infectious Agent
14%
Influenza A
11%
Influenza B
9%
Influenza Vaccine
8%
Interleukin 6
12%
Lactam
12%
Lactobacillus
9%
Lung Disease
61%
Macrolide
26%
Methicillin-Resistant Staphylococcus Aureus
9%
Minimum Inhibitory Concentration
12%
Minocycline
8%
Mouse
35%
Mycobacteria
8%
Mycobacterium abscessus
8%
Mycobacterium Avium Complex
82%
Mycobacterium Intracellulare
10%
Mycoplasma Pneumonia
14%
Norfloxacin
7%
Penicillin Derivative
19%
Pharmacokinetics
41%
Placebo
7%
Pneumococcal Infection
23%
Pneumococcus Vaccine
14%
Prematurity
17%
Prevalence
17%
Respiratory Tract Infection
17%
Retrospective Study
11%
Rifampicin
9%
SARS Coronavirus
24%
Schistosomiasis Mansoni
8%
Side Effect
12%
Staphylococcus Aureus
11%
Streptococcus Agalactiae
9%
Streptococcus Pneumoniae
22%
Streptococcus pyogenes
8%
Symptom
22%
Tebipenem Pivoxil
26%
Technetium 99m
8%
Tosufloxacin
15%
Toxoplasmosis
8%
Tuberculosis
10%
Tumor Necrosis Factor
11%
Urinary Tract Infection
9%
Vaccination Policy
14%
Vancomycin
12%
Vasculotropin
8%
Medicine and Dentistry
Acute Lung Injury
8%
Acute Respiratory Distress Syndrome
12%
Adverse Event
19%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Amikacin
15%
Antibiotic Resistance
9%
Antibiotic Therapy
8%
Antibiotics
10%
Antiinfective Agent
23%
Antimicrobial Therapy
9%
Artificial Respiration
9%
Atypical Mycobacterium
19%
Bacteremia
18%
Bacterial Infection
12%
Biological Marker
6%
Blood Culture
9%
Body Mass Index
7%
Bronchiectasis
18%
Bronchoalveolar Lavage Fluid
19%
C Reactive Protein
10%
Cholangitis
8%
Chronic Kidney Disease
6%
Chronic Obstructive Pulmonary Disease
14%
Clarithromycin
8%
Clinical Feature
12%
Cohort Analysis
8%
Combination Therapy
10%
Community-Acquired Pneumonia
14%
Computer Assisted Tomography
10%
COVID-19
85%
COVID-19 Vaccination
9%
COVID-19 Vaccine
8%
Cross Sectional Study
18%
Diagnosis
13%
Diarrhea
9%
Diethylstilbestrol
8%
Disease
64%
Disease Course
7%
Disease Exacerbation
14%
Disease Severity
10%
Drug Therapy
10%
Dysentery
8%
Entamoeba Histolytica
6%
Epithelial Lining Fluid
8%
Ethambutol
6%
Gut
13%
Health Care Cost
6%
Hematopoietic Stem Cell Transplantation
6%
Human Immunodeficiency Virus
11%
Idiopathic Interstitial Pneumonia
7%
Idiopathic Pulmonary Fibrosis
11%
Infection
47%
Intensive Care Unit
6%
Interleukin 6
11%
Lactobacillus
8%
Leukocyte
7%
Liver Transplantation
8%
Lung Cancer
14%
Lung Emphysema
6%
Lung Function
6%
Lung Function Test
6%
Lung Infection
6%
Lung Lesion
6%
Lymphocyte
8%
Macrolide
9%
Mixed Infection
6%
Mycobacteria
15%
Mycobacterium abscessus
15%
Mycobacterium Avium Complex
89%
Mycobacterium Avium-Intracellulare Infection
6%
Nasopharyngeal Swab
8%
Neutrophil
8%
Observational Study
9%
Odds Ratio
18%
Outpatient
8%
Pathogen
25%
Pediatrics
6%
Physician
9%
Pneumococcal Infection
11%
Pneumonectomy
10%
Pneumonia
6%
Pneumothorax
8%
Polymerase Chain Reaction
8%
Polymerase Chain Reaction
6%
Prevalence
12%
Quality of Life
15%
Real Time Polymerase Chain Reaction
13%
Recurrent Disease
8%
Retrospective Cohort Study
23%
Retrospective Study
9%
Severe Acute Respiratory Syndrome Coronavirus 2
21%
Silo-Filler's Disease
85%
St. George Respiratory Questionnaire
10%
Streptococcus Pneumoniae
8%
Surgery
11%
Survival Rate
6%
Symptom
14%
Tocilizumab
8%
Treatment Duration
6%
Tumor Necrosis Factor
6%
Keyphrases
Acute Lung Injury
14%
Acute Respiratory Distress Syndrome
8%
Adjusted Odds Ratio
8%
AIDS/HIV
6%
Amoeba
6%
Antibacterial Susceptibility
8%
Antibiotic Use
6%
Antimicrobial Stewardship
6%
Antimicrobial Susceptibility
6%
Aphidicolin
9%
Bacterial Infection
8%
Bacterial Pneumonia
8%
Bacterial Respiratory Pathogens
8%
Bacteriological Examination
10%
Bronchiectasis
7%
Bronchoalveolar Lavage Fluid
11%
Causative Organisms
7%
CD11b+Gr1+ Cells
8%
Ceftazidime
13%
Chemotherapy
21%
Chronic Obstructive Pulmonary Disease
7%
Clarithromycin
6%
Clinical Characteristics
8%
Clinical Efficacy
9%
Clinical Evaluation
15%
Clinical Microbiology
8%
Community-acquired Pneumonia
19%
Comorbidity
7%
Confidence Interval
14%
COVID-19
44%
COVID-19 Outcomes
6%
COVID-19 Severity
10%
Diarrhea
10%
Dinitroaniline Herbicides
8%
Disease Severity
9%
Drip Infusion
7%
E.histolytica
8%
Elastase
7%
Encystation
9%
Endotoxin
8%
Entamoeba Histolytica
13%
Entamoeba Invadens
17%
Epithelial Lining Fluid
13%
Excystation
17%
Gentamicin
6%
Haemophilus Influenzae
13%
Hospitalized Patients
7%
Host Biomarkers
8%
Immunoglobulin G2
8%
Infectious Diseases
18%
Interleukin-6
8%
Interstitial Pneumonia
6%
Intravenous Drip
6%
Invasive Mechanical Ventilation
9%
Invasive Pneumococcal Disease
10%
Japan
71%
Japanese Adults
9%
Japanese Patients
9%
Japanese Population
6%
Japanese Society
13%
Krebs Von Den Lungen-6 (KL-6)
10%
Liver Transplantation
8%
Lung
13%
Lung Cancer
7%
Mycobacteria Growth Indicator Tube
6%
Mycobacterium Avium Complex
10%
Mycobacterium Avium Complex Lung Disease
10%
Mycobacterium Avium Complex Pulmonary Disease
8%
Mycobacterium Intracellulare
18%
Mycolicibacterium
8%
Nationwide Surveillance
8%
Nationwide Survey
9%
Neonatal Infants
17%
Neonate
9%
Nontuberculous Mycobacterial Infection
13%
Nontuberculous Mycobacterial Lung Disease
28%
Odds Ratio
8%
Oryzalin
8%
Otitis Media
8%
Patient Characteristics
10%
Patients with COVID-19
14%
PCV7
7%
Pediatric
22%
Pediatric Patients
14%
Pharmacokinetic Evaluation
8%
Pharmacokinetics
15%
Pharmacokinetics-pharmacodynamics (PK-PD)
8%
Pneumococcal Conjugate Vaccine
6%
Pneumonia
6%
Premature Infant
13%
Prognostic Significance
8%
Respiratory Infection
8%
Retrospective Cohort Study
10%
Rifampicin
7%
Serum Concentration
9%
St. George's Respiratory Questionnaire
8%
Streptococcus Pneumoniae
14%
Tebipenem pivoxil
22%
Vaccine Serotypes
8%
β-lactamase
9%